



## City Research Online

### City, University of London Institutional Repository

---

**Citation:** Terheyden, J. H., Schmitz-Valckenberg, S., Crabb, D. P., Dunbar, H., Luhmann, U. F. O., Behning, C., Schmid, M., Pires, I., Cunha-Vaz, J., Tufail, A., et al (2020). Use of composite endpoints in early and intermediate age-related macular degeneration clinical trials - state-of-the-art and future directions. *Ophthalmologica*, doi: 10.1159/000513591

This is the published version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <https://openaccess.city.ac.uk/id/eprint/26015/>

**Link to published version:** <https://doi.org/10.1159/000513591>

**Copyright:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

**Reuse:** Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.



# Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions

Jan Henrik Terheyden<sup>a</sup> Steffen Schmitz-Valckenberg<sup>a,b</sup> David P. Crabb<sup>c</sup> Hannah Dunbar<sup>d</sup>  
Ulrich F.O. Luhmann<sup>e</sup> Charlotte Behning<sup>f</sup> Matthias Schmid<sup>f</sup> Rufino Silva<sup>g-i</sup> José Cunha-Vaz<sup>g</sup>  
Adnan Tufail<sup>j</sup> Georges Weissgerber<sup>k</sup> Sergio Leal<sup>l</sup> Frank G. Holz<sup>a</sup> Robert P. Finger<sup>a</sup>  
on behalf of the MACUSTAR Consortium

<sup>a</sup>Department of Ophthalmology, University Hospital Bonn, Bonn, Germany; <sup>b</sup>John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA; <sup>c</sup>Division of Optometry and Visual Sciences, School of Health Sciences, City University of London, London, UK; <sup>d</sup>UCL Institute of Ophthalmology, London, UK; <sup>e</sup>Roche Pharmaceutical Research and Early Development, Translational Medicine Ophthalmology, Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland; <sup>f</sup>Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany; <sup>g</sup>Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal; <sup>h</sup>University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCIBR), Faculty of Medicine, Coimbra, Portugal; <sup>i</sup>Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; <sup>j</sup>Moorfields Eye Hospital, London, UK; <sup>k</sup>Novartis Pharma AG, Basel, Switzerland; <sup>l</sup>Bayer AG, Berlin, Germany

## Keywords

Age-related macular degeneration · Composite end points · Trial outcomes

## Abstract

The slow progression of early age-related macular degeneration (AMD) stages to advanced AMD requires the use of surrogate end points in clinical trials. The use of combined end points may allow for shorter and smaller trials due to increased precision. We performed a literature search for the use of composite end points as primary outcome measures in clinical studies of early AMD stages. PubMed was searched for composite end points used in early/intermediate AMD studies published during the last 10 years. A total of 673 ar-

ticles of interest were identified. After reviewing abstracts and applicable full-text articles, 33 articles were eligible and thus included in the qualitative synthesis. The main composite end point categories were: combined structural and functional end points, combined structural end points, combined functional end points and combined multicategorical end points. The majority of the studies included binary composite end points. There was a lack of sensitivity analyses of different end points against accepted outcomes (i.e., progression) in the literature. Various composite outcome measures have been used but there is a lack of standardization. To date no agreement on the optimal approach to implement combined end points in clinical studies of early stages of AMD exists, and no surrogate end points have been accepted for AMD progression.

© 2020 The Author(s)  
Published by S. Karger AG, Basel

## Introduction

Age-related macular degeneration (AMD) is one of the major causes of visual loss in the elderly worldwide, impairing physical, emotional and social well-being of those affected [1–3]. Due to population aging, patient numbers are expected to increase significantly over the next decades [4, 5]. While people with early stages of AMD are often asymptomatic under everyday lighting conditions, individuals with advanced AMD may develop irreversible central scotoma due to atrophy of outer retinal layers or choroidal neovascularization [2, 6, 7]. At present, therapies are only available for neovascular AMD. However, new therapies preventing nonadvanced disease from progressing are required to reduce the global burden of blindness due to AMD.

No clinical trial end points have been developed for this indication yet. In neovascular AMD trials, high luminance high contrast best-corrected visual acuity (BCVA) is an end point accepted by the regulatory authorities but BCVA is not sensitive enough to measure the functional deficit specific to early and intermediate AMD. Those are stages in which BCVA is largely unaffected but the visual deficit is prominent under low luminance or low contrast conditions [6, 7]. Progression from early AMD stages to advanced AMD is a slow process [8]. Thus, new surrogate end points for the progression of early and intermediate AMD to advanced AMD are needed [9].

Various end points, including structural, functional and patient-reported variables, have been implemented in previous studies of early AMD stages [10–19]. Composite end points summarize single end points across these different categories, increasing the overall sensitivity of the end point for reaching accepted outcomes (i.e., progression). If used in clinical trials, more sensitive composite end points would thus allow for smaller and shorter trials to be performed, without a reduction in statistical power [20, 21]. Sophisticated composite end points have been proposed for longitudinal studies in glaucoma but their relevance to current AMD research is unclear [22]. In order to assess the current state of relevant available research we reviewed the literature for the use of composite end points as primary outcome measures in clinical studies of early AMD stages.

## Methods

PubMed was searched in August 2020 using the following search terms: age-related macular degeneration, early, intermediate, nonexudative, nonadvanced, Age-Related Eye Disease Study

(AREDS) 2/3, end point, outcome and biomarker. All relevant abstracts were reviewed, and full-text articles were downloaded when indicated. Inclusion criteria were interventional or longitudinal studies on early or intermediate AMD including primary composite end points. Only studies published within the last 10 years were considered. Exclusion criteria were articles dealing primarily with neovascular AMD, geographic atrophy or diseases other than AMD, articles focusing mainly on serum biomarkers as well as articles in languages other than English.

## Results

Our initial search yielded a total of 673 articles of interest. After screening the abstracts, 601 articles did not meet the inclusion criteria and were therefore excluded. We thus assessed 72 full-text articles for eligibility. Thirty-nine of these articles were excluded based on full-text assessment. Reasons for exclusion were: 25 studies did not implement composite end points, 4 investigated a healthy cohort, 3 were cross-sectional studies, 2 included participants with only late AMD, 2 were reviews, 1 was focused on serum biomarkers, 1 was focused on device-related instead of disease-related outcomes, 1 investigated single cases only. Thus, we included 33 articles in the qualitative synthesis. Twenty-two of these articles were published between 2016 and 2020 while 11 articles were published between 2010 and 2015.

### *Combined Structural and Functional Outcomes*

Our search revealed 8 articles (7 studies) that implemented combinations of structural and functional outcome measures (Table 1); 4 of the studies were interventional [10–15, 19, 23]. Chew et al. [10, 12] combined fundus photography-based structural outcome measures providing evidence of progression to late AMD with BCVA loss in follow-up reports of the AREDS. Nittala et al. [14] combined thickness assessment of the retinal pigment epithelium (RPE)-drusen complex on optical coherence tomography and low luminance visual acuity in a longitudinal cohort study of 85 fellow eyes of neovascular AMD eyes. Robinson et al. [13] used onset of late AMD, increase in drusen volume and changes in the cone time constant in adaptometry as primary co-outcome measures in a randomized trial of light therapy with 60 participants [23]. Guymer et al. [11] investigated the primary outcome measures BCVA, drusen area and macular sensitivity on flicker perimetry in a pilot trial on nanosecond laser therapy with 50 participants. Recently, Saßmannshausen et al. [15] investigated point-wise sensitivity changes and retinal thickness changes as main outcome measures in a longitu-

**Table 1.** Composite end points identified in systematic literature search (2010–2020)

| Authors  | Year | Composite outcomes   | Study type      | Sample  |
|--|------|--|-----------------|---|
| <i>Combined structural and functional outcomes</i> |      |  |                 |   |
| Chew et al. [10]                                   | 2013 | Progression to nvAMD, progression to central GA, visual acuity loss $\geq 15$ letters  | RCT             | 10-year follow-up of 4,757 AREDS participants   |
| Chew et al. [12]                                   | 2014 | Progression to nvAMD, progression to central GA, visual acuity loss $\geq 15$ letters  | RCT             | 10-year follow-up and risk factor assessment of 4,757 AREDS participants                              |
| Guymier et al. [11]                                | 2014 | Best-corrected VA, drusen area, macular sensitivity in flicker perimetry   | Interventional  | 1-year pilot study on nanosecond laser therapy in 50 participants with bilateral iAMD                 |
| Robinson et al. [13]                               | 2018 | Progression to nvAMD, increased drusen volume, change in time constant of cone dark adaptation                               | RCT             | 1-year phase I/IIa study on light therapy in 60 early AMD eyes with nvAMD fellow eyes                 |
| Nittala et al. [14]                                | 2019 | Retinal layer thickness change, VA change  | Natural history | 2-year study of 85 eyes with nvAMD fellow eyes  |
| Saßmannshausen et al. [15]                         | 2020 | Point-wise correlation of retinal sensitivity to corresponding standardized point-wise retinal thickness                     | Natural history | 3-year structure-function correlation study of 59 iAMD eyes   |
| Saßmannshausen et al. [15]                         | 2020 | Point-wise correlation of retinal sensitivity to corresponding standardized point-wise retinal thickness                     | Natural history | 3-year structure-function correlation study of 30 iAMD eyes with predominantly reticular pseudodrusen |
| <i>Combined structural outcomes</i>                |      |  |                 |   |
| Alexandre de Amorim Garcia Filho et al. [37]       | 2013 | Changes in drusenoid pigment epithelial detachment area, progression to nvAMD, progression to GA                             | Natural history | Longitudinal study of drusenoid pigment epithelial detachments in 186 eyes with nonadvanced AMD       |
| Guymier et al. [24]                                | 2013 | Progression to nvAMD, progression to GA, progression to higher severity scores of non-advanced AMD                           | RCT             | 3-year study on simvastatin use in 114 participants with iAMD   |
| Seddon et al. [38]                                 | 2013 | Progression to nvAMD, progression to GA  | Validation      | 5- and 10-year analysis of 2,914 AMD participants and predictive modeling                             |
| Myers et al. [32]                                  | 2014 | Progression on the 3 continent AMD consortium age-related macular degeneration severity scale                                | Natural history | 20-year analysis of 4,439 participants from the Beaver Dam Eye Study, focusing on cigarette smoking   |
| Wu et al. [17]                                     | 2014 | Subsidence of the OPL and inner nuclear layer; development of a hyporeflexive wedge-shaped band within the limits of the OPL | Validation      | Retrospective analysis of 16 AMD eyes before development of geographic atrophy                        |
| Joachim et al. [34]                                | 2015 | Progression to nvAMD, progression to GA  | Natural history | 15-year analysis of 2,474 population-based participants of the Blue Mountains Eye Study               |
| Abdelfattah et al. [36]                            | 2016 | Progression to nvAMD, progression to GA  | Validation      | Retrospective 2-year analysis of 89 early/iAMD eyes with nvAMD fellow eyes focusing on drusen volume  |
| Folgar et al. [25]                                 | 2016 | Progression to nvAMD, progression to GA  | Validation      | 2-year analysis of RPE-DC including 345 AMD eyes from the AREDS 2 ancillary SD-OCT study              |
| Liew et al. [35]                                   | 2016 | Progression to nvAMD, progression to GA  | Natural history | 5- and 10-year analysis of 3,640 participants from the AREDS and the Blue Mountains Eye Study         |

**Table1** (continued)

| Authors   | Year | Composite outcomes  | Study type      | Sample   |
|---|------|---|-----------------|--|
| Veerappan et al. [18]   | 2016 | Pre-atrophic OCT findings, progression to (central) GA, progression to nvAMD        | Validation      | 3-year analysis of reflective drusen substructures including 349 AMD eyes from the AREDS 2 ancillary SD-OCT study  |
| Burlina et al. [33]   | 2018 | Progression to nvAMD, progression to GA   | Validation      | 5-year analysis of fundus photographs and risk of progression using a deep learning approach in 4,613 AREDS participants   |
| Joachim et al. [28]   | 2018 | ≥1-step/≥2-step progression on the 3 continent AMD consortium 5-step severity scale | Natural history | 10-year analysis of 835 participants at early AMD stages from the Blue Mountains Eye Study and Rotterdam Study   |
| Schmidt-Erfurth et al. [26]                                     | 2018 | Progression to nvAMD, progression to GA   | Validation      | 2-year analysis of quantitative OCT features preceding progression in 495 iAMD eyes  |
| Chiang et al. [30]  | 2020 | Modified AREDS severity scale   | Validation      | Includes a 4-year analysis of macular thickness in 77 eyes with no to intermediate AMD   |
| Kim et al. [41]   | 2020 | Drusen area, pigment epithelial detachment height                                   | Interventional  | 12-month report of efficacy and safety of laser photocoagulation and antivascular endothelial growth factor in 20 patients with drusenoid pigment epithelial detachments |
| Nassisi et al. [40]   | 2019 | Progression to nvAMD, progression to GA   | Validation      | 2-year post hoc analysis of 501 early/iAMD fellow eyes of nvAMD eyes included in the HARBOR study  |
| Piatti et al. [27]  | 2020 | Macular hemorrhage, progression of atrophic areas                                   | RCT             | 2-year nutritional supplementation study in 74 participants with iAMD  |
| Sitnilska et al. [39]   | 2020 | Progression to nvAMD, progression to GA   | Validation      | Longitudinal study of CFP, SD-OCT and IR imaging in 232 early/iAMD participants  |
| Thiele et al. [29]  | 2020 | Progression to nvAMD, progression to GA   | Validation      | 6-year study of retinal layer thicknesses in 91 early/iAMD eyes  |
| Waldstein et al. [31]   | 2020 | Progression to nvAMD, progression to macular GA                                     | Validation      | 2-year analysis of quantitative OCT features preceding progression in 309 early/iAMD eyes with nvAMD fellow eyes included in the HARBOR study                            |
| <i>Combined functional outcomes</i><br>Wu et al. [6]            | 2015 | Retinal sensitivity (microperimetry), low-luminance VA                              | Natural history | 1-year study of 41 participants with iAMD and 8 participants with extrafoveal GA   |
| Hsu et al. [42]   | 2019 | Multiple functional assessments   | Natural history | 1-year study including 66 early/iAMD participants  |
| <i>Combined multicategorical outcomes</i><br>Finger et al. [43] | 2019 | Multiple structural, functional and patient-reported assessments                    | Natural history | 3-year study of 650 early/iAMD participants ( <i>description of study protocol</i> )   |
| Curcio et al. [45]  | 2020 | Multiple structural, functional and patient-reported assessments                    | Natural history | 3-year study of 480 normal aging changes/early AMD participants ( <i>description of study protocol</i> )   |

AREDS, Age-Related Eye Disease Study; CFP, color fundus photography; GA, geographic atrophy; iAMD, intermediate age-related macular degeneration; IR, infrared; nvAMD, neovascular age-related macular degeneration; OPL, outer plexiform layer; RCT, randomized, controlled trial; RPE/DC, retinal pigment epithelium-drusen complex; SD-OCT, spectral-domain optical coherence tomography; VA, visual acuity.



dinal study of 54 patients with intermediate AMD and in 25 patients with intermediate AMD and predominantly subretinal drusenoid deposits [19].

#### *Combined Structural Outcomes*

We identified 20 articles focusing on combined structural outcome measures (Table 1), 3 of which were interventional [17, 18, 24–41]. Twelve of these 20 articles included progression to late-stage AMD (development of choroidal neovascularization or geographic atrophy) as a composite end point [25–27, 29, 31, 33–36, 38–40]. Four of the articles reported the use of specific severity scales based on the anatomical AMD classification and implementing an additive structure (including increased drusen size and/or pigmentation as well as progression to late AMD) as the main outcome measure [24, 28, 30, 32]. Four other reports combined structural outcome measures different from the ones described. Wu et al. [17] defined 2 optical coherence tomography-based biomarkers (subsidence of the outer plexiform layer and inner nuclear layer and development of a hyporeflective wedge-shaped band within the limits of the outer plexiform layer) and combined them to the outcome measure “nascent geographic atrophy” in their analysis of 181 participants. Veerappan et al. [18] used a set of pre-atrophic findings (including RPE-drusen complex thinning, RPE disruption, photoreceptor layer thinning) and progression to late-stage AMD as primary outcome measures in their analysis of 349 participants of the ARED Study 2 ancillary spectral-domain optical coherence tomography study. Alexandre de Amorim Garcia Filho et al. [37] combined progression to late AMD with changes of the area of pigment epithelial detachments on optical coherence tomography to a main outcome measure. Kim et al. [41] combined drusen area on fundus photography and pigment epithelial detachment height on optical coherence tomography as primary co-outcomes.

#### *Combined Functional Outcomes*

Two studies combined different functional outcomes (Table 1). Wu et al. [6] described pointwise sensitivities obtained from fundus-controlled perimetry (microperimetry) as well as low luminance visual acuity (LLVA) in a longitudinal study of 49 participants with nonadvanced AMD. Hsu et al. [42] investigated several functional end points (BCVA, LLVA, low luminance deficit, percent-reduced threshold and average threshold from fundus-controlled perimetry as well as cone contrast tests) in 85 participants with early/intermediate AMD and healthy control participants longitudinally.

#### *Combined Multicategorical Outcomes*

In addition, we identified 3 reports that included end points from more than 1 of the outcome categories mentioned above (Table 1). Two reports described the MA-CUSTAR study, a longitudinal study validating various functional, structural and patient-reported outcome measures in a large cohort of intermediate AMD patients which is still ongoing [43, 44].

Curcio et al. [45] described the use of various outcomes (obtained from rod-mediated dark adaptation, 2-color dark-adapted microperimetry, light-adapted perimetry, photopic acuity, mesopic acuity, photopic contrast sensitivity, mesopic contrast sensitivity, color fundus photography, near-infrared reflectance, optical coherence tomography angiography, quantitative autofluorescence, low luminance questionnaire, Vision in Low Luminance questionnaire and other assessments) in the Alabama Study on Early Age-Related Macular Degeneration 2 (ALSTAR2) which is also ongoing.

#### *Sensitivity of Composite End Points*

None of the articles compared sensitivities of single end points for reaching accepted outcomes to sensitivities of composite end points.

## **Discussion**

Several variations of combined outcome measures and composite end points have been used in clinical studies of early and intermediate AMD. The most frequent combinations were those of various structural end points, followed by combinations of structural and functional end points. However, no structural clinical trial end point except the relatively rare event of progression to advanced neovascular or atrophic AMD is currently accepted by regulatory authorities and health technology assessment bodies [43]. Due to increasing numbers of patients with AMD, new therapies are urgently required and for this, validated end points are a prerequisite to enable future therapeutic developments [4].

In the 2017 National Eye Institute/United States Food and Drug Administration end point workshop on AMD, the potential benefit of using surrogate end points as predictors of a clinically meaningful outcome (such as photoreceptor loss) was highlighted [7]. We have identified several combined AMD outcome measures used as surrogates for the loss of photoreceptors reported in the literature. The majority are simple binary outcome measures indicating that a catalogue of single yes- or no-type

end points are combined [20, 21]. Usually, the overall end point is reached when at least one of the single end points is reached (Boolean OR operator). An example used by many of the studies identified in our review is conversion to late AMD which includes the single end points “conversion to neovascular AMD” and “conversion to geographic atrophy” [25–27, 29, 39, 46]. This composite end point reflects the strong association between vision loss and the presence of any advanced disease stage [1, 3] and is an accepted end point by regulatory authorities [43]. However, due to the relatively slow progression of AMD (on average 5–20 events per 100 person-years) and the need for shorter trial durations for novel future therapeutics [43, 47], it is unsuitable for studies of early or intermediate AMD. Thus, end points associated with earlier AMD disease stages and with a high sensitivity for progression are required. Progression of classic structural parameters such as drusen size or hyperpigmentation (and their correlates on optical coherence tomography) do not show strong enough associations with vision loss to be acceptable to regulators [48]. The composite end point nascent geographic atrophy appears to be a promising predictor of atrophy development, yet it is not associated with neovascular AMD and does not include a functional dimension, as desired by regulatory agencies [7, 17]. With respect to functional end points, BCVA has been shown to be insensitive to the deficit specific to early AMD stages and seems to be inappropriate both as a single end point and as part of an intermediate AMD-targeted composite end point from what is currently known [6, 7]. Other functional variables like LLVA, microperimetry and dark adaptometry appear more promising but lack data over the long term [6, 11, 13, 15]. In summary, we have found different approaches of using binary outcome measures in the literature but none seems to be ready for use in prospective large-scale clinical trials.

Another potential composite end point category is continuous end points which use scores calculated from the single end points of different levels of measurement. Composite scores have been sparsely used in AMD studies to date. However, continuous composite end points have a high potential because they allow integration of different outcome categories and thus can lead to an increase in statistical power within treatment studies when carefully validated [49]. Sensitivity testing and a validation of different composite end points in AMD research have yet to be performed which is why the MACUSTAR and ALSTAR2 studies as well as the AMD Ryan Initiative Study (ARIS) are currently being conducted [43–45, 50].

Similarly to composite end points, a variety of single outcomes have been associated with progression to late-stage disease [3, 36, 51–64]. Schaal et al. [65] have published a comprehensive review of anatomical end points in nonexudative AMD. Overall, many different composite end points are available in the literature, but broader consensus definitions of AMD outcome measures are required [7].

The use of composite end points is also met with interest in other areas of ophthalmology. Due to the absence of a gold standard of determining physiological changes versus disease progression, glaucoma researchers use surrogate end points regularly including intraocular pressure and certain visual field indices [66]. These single surrogate end points can be combined to composite scores. Such composite end points in glaucoma have been demonstrated to increase accuracy of prediction of progression, reduce measurement variability and require smaller sample sizes than single end points derived from, for example, perimetry [22, 67]. Similarly, the role of surrogate end points as well as composite end points in clinical studies of dry eye disease is growing [68, 69]. Specifically, various clinical scores are used as end points, enabling the development of continuous composite end points [68].

Beyond ophthalmology, composite end points have been met with considerable interest in the context of Alzheimer’s disease where combined cognitive and functional outcome measures have gained in importance over the last few years [70]. An analysis of 2 expedited pharmaceuticals approval pathways of the European Medicines Agency across specialities between 2011 and 2018 showed that the majority of authorizations was based on surrogate end points, and a relevant number of authorizations included composite end points [71]. Thus, reliable and valid composite end points are required to enable future therapeutic developments in intermediate AMD, which represent a huge unmet need.

The strengths of our work include the systematic review of the available literature as well as the data synthesis and categorization into different types of composite end points. The focused search of only one data base (PubMed) may limit generalizability of results and reduce completeness. However, a high number of relevant studies can generally be expected to be published in journals indexed in PubMed.

In conclusion, the use of composite end points and combined outcome measures in longitudinal and interventional studies of early and intermediate AMD is increasing. Various composite measures have been used but there is a lack of standardization and validation. To date no agreement on the best approach to implement combined end points in clinical trials of early stages of AMD exists.



## MACUSTAR Consortium Members

P. Basile, C. Behning, M. Berger, A. Binns, M. Böttger, C. Bouchet, J.E. Brazier, T. Butt, C. Carapezzi, J. Carlton, A. Charil, R. Coimbra, S. Nunes, D.P. Crabb, J. Cunha-Vaz, H. Dunbar, M. Durbin, R.P. Finger, F.G. Holz, C. Hoyng, J. Krätzschar, S. Leal, U. Luhmann, A. Lüning, C. Martinho, B. Melício, S. Pondorfer, S. Mohand-Said, M. Pfau, D. Rowen, G.S. Rubin, J. Sahel, C. Sánchez, D. Sanches Fernandes, M. Saßmannshausen, M. Schmid, S. Schmitz-Valckenberg, H. Schrinner-Fenske, A. Skelly, L. Stöhr, D. Tavares, D.J. Taylor, J.H. Terheyden, S. Thiele, A. Tufail, G. Weissgerber, L. Wintergerst, C. Wojek, N. Zakaria.

## Acknowledgments

We are very grateful for the continuous support provided by Nathalie Seigneuret at the IMI Office in Brussels. We also gratefully acknowledge the work put into this project by consortium members who have since moved on to work elsewhere.

## Disclaimer

The communication reflects the author's view, and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained therein.

## Conflict of Interest Statement

J.H.T.: Heidelberg Engineering, Optos, Zeiss Meditec, CenterVue. S.S.-V.: Acucela/Kubota Vision Apellis, Novartis, Allergan, Bayer, Bioeq/Formycon, Carl Zeiss Meditec, CenterVue, Galime-

dix, Roche; Heidelberg Engineering, Katairo, Optos, Oxurion, Roche/Genentech. D.P.C.: Allergan, Roche, Santen, Centervue. H.D.: Boehringer-Ingelheim. U.F.O.L.: employee of F. Hoffmann-La Roche Ltd. C.B.: none. M.S.: Pixum Vision. R.S.: Allergan, Alimera Sciences, Bayer, Novo Nordisk, Novartis, Thea, Roche. J.C.-V.: Aerpio Therapeutics, Alimera Sciences, Allergan, Bayer, Boehringer-Ingelheim, Novartis, Zeiss Meditec, Oxular Ltd. A.T.: none. G.W.: employee of Novartis Pharma AG. S.L.: employee of Bayer AG. F.G.H.: Acucela, Allergan, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Grayburg Vision, Heidelberg Engineering, Kanghong, LinBioscience, NightStarX, Novartis, Optos, Pixium, Vision, Oxurion, Stealth BioTherapeutics, Zeiss. R.P.F.: Novartis, Bayer, Allergan, Alimera, Roche/Genentech, Santhera, Opthea, Inositec, Ellex, CentreVue, Zeiss, Heidelberg Engineering.

## Funding Sources

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking 439 under grant agreement No. 116076. This Joint Undertaking receives support from the 440 European Union's Horizon 2020 research and innovation programme and EFPIA.

## Author Contributions

F.G.H., R.P.F., S.S.-V., M.S., U.F.O.L., D.P.C., H.D., A.T., J.C.-V. and R.S. designed the study. J.H.T. compiled the data set. J.H.T., R.P.F., S.S.-V., C.B., D.P.C., S.L. and M.S. wrote the manuscript. All authors contributed substantially to the conception or design of the study, data acquisition, data analysis or data interpretation as well as to drafting the manuscript or critically revising it. They approved the final version to be published.

## References

- 1 Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al.; Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. *Lancet Glob Health*. 2013 Dec;1(6):e339-49.
- 2 Colijn JM, Buitendijk GH, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al.; EYE-RISK consortium; European Eye Epidemiology (E3) consortium. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. *Ophthalmology*. 2017 Dec;124(12):1753-63.
- 3 Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. *Health Qual Life Outcomes*. 2006 Dec;4(1):97.
- 4 Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. *Br J Ophthalmol*. 2020 Aug;104(8):1077-84.
- 5 Brandl C, Stark KJ, Wintergerst M, Heineemann M, Heid IM, Finger RP. Epidemiologie der altersbedingten Makuladegeneration. *Ophthalmologie*. 2016 Sep;113(9):735-45.
- 6 Wu Z, Ayton LN, Luu CD, Guymer RH. Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration. *JAMA Ophthalmol*. 2015 Apr;133(4):442-8.
- 7 Csaky K, Ferris F 3rd, Chew EY, Nair P, Cheetham JK, Duncan JL. Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases. *Invest Ophthalmol Vis Sci*. 2017 Jul;58(9):3456-63.
- 8 Tikellis G, Robman LD, Dimitrov P, Nicolas C, McCarty CA, Guymer RH. Characteristics of progression of early age-related macular degeneration: the cardiovascular health and age-related maculopathy study. *Eye (Lond)*. 2007 Feb;21(2):169-76.
- 9 Wickström K, Moseley J. Biomarkers and Surrogate Endpoints in Drug Development: A European Regulatory View. *Invest Ophthalmol Vis Sci*. 2017;58(6):BIO27-33.
- 10 Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Kurinij N, et al.; Age-Related Eye Disease Study Research Group. Long-term effects of vitamins C and E,  $\beta$ -carotene, and zinc on age-related macular degeneration: AREDS report no. 35. *Ophthalmology*. 2013 Aug;120(8):1604-11.e4.
- 11 Guymer RH, Brassington KH, Dimitrov P, Makeyeva G, Plunkett M, Xia W, et al. Nano-second-laser application in intermediate AMD: 12-month results of fundus appearance and macular function. *Clin Exp Ophthalmol*. 2014 Jul;42(5):466-79.

- 12 Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Davis MD, et al.; Age-Related Eye Disease Study Research Group. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. *JAMA Ophthalmol*. 2014 Mar;132(3):272–7.
- 13 Robinson DG, Margrain TH, Dunn MJ, Bailey C, Binns AM. Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial. *Invest Ophthalmol Vis Sci*. 2018 Sep;59(11):4531–41.
- 14 Nittala MG, Hogg RE, Luo Y, Velaga SB, Silva R, Alves D, et al. Changes in Retinal Layer Thickness in the Contralateral Eye of Patients with Unilateral Neovascular Age-Related Macular Degeneration. *Ophthalmol Retina*. 2019 Feb;3(2):112–21.
- 15 Saßmannshausen M, Zhou J, Pfau M, Thiele S, Steinberg J, Fleckenstein M, et al. Longitudinal analysis of retinal thickness and retinal function in eyes with large drusen secondary to intermediate age-related macular degeneration. *Ophthalmol Retina*. 2020, Online ahead of print.
- 16 de Sisternes L, Simon N, Tibshirani R, Leng T, Rubin DL. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. *Invest Ophthalmol Vis Sci*. 2014 Oct;55(11):7093–103.
- 17 Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC, et al. Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. *Ophthalmology*. 2014 Dec;121(12):2415–22.
- 18 Veerappan M, El-Hage-Sleiman AM, Tai V, Chiu SJ, Winter KP, Stinnett SS, et al.; Age-related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Optical Coherence Tomography Reflective Drusen Substructures Predict Progression to Geographic Atrophy in Age-related Macular Degeneration. *Ophthalmology*. 2016 Dec;123(12):2554–70.
- 19 Sassmannshausen M, Pfau M, Thiele S, Fimmers R, Steinberg JS, Fleckenstein M, et al. Longitudinal Analysis of Structural and Functional Changes in Presence of Reticular Pseudodrusen Associated With Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2020 Aug;61(10):19.
- 20 Chi GY. Some issues with composite endpoints in clinical trials. *Fundam Clin Pharmacol*. 2005 Dec;19(6):609–19.
- 21 Sankoh AJ, Li H, D'Agostino RB Sr. Use of composite endpoints in clinical trials. *Stat Med*. 2014 Nov;33(27):4709–14.
- 22 Russell RA, Malik R, Chauhan BC, Crabb DP, Garway-Heath DF. Improved estimates of visual field progression using bayesian linear regression to integrate structural information in patients with ocular hypertension. *Invest Ophthalmol Vis Sci*. 2012 May;53(6):2760–9.
- 23 McKeague C, Margrain TH, Bailey C, Binns AM. Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial. *Trials*. 2014 Jun;15(1):246.
- 24 Guymer RH, Baird PN, Varsamidis M, Busija L, Dimitrov PN, Aung KZ, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. *PLoS One*. 2013;8(12):e83759.
- 25 Folgar FA, Yuan EL, Sevilla MB, Chiu SJ, Farsiu S, Chew EY, et al.; Age Related Eye Disease Study 2 Ancillary Spectral-Domain Optical Coherence Tomography Study Group. Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration. *Ophthalmology*. 2016 Jan;123(1):39–50.e1.
- 26 Schmidt-Erfurth U, Waldstein SM, Klimesch S, Sadeghipour A, Hu X, Gerendas BS, et al. Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence. *Invest Ophthalmol Vis Sci*. 2018 Jul;59(8):3199–208.
- 27 Piatti A, Croce A, Mazzacane D, Traina G, Ambrosino L, Boni L, et al. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. *Eur J Ophthalmol*. 2020 Mar;30(2):376–81.
- 28 Joachim N, Kifley A, Colijn JM, Lee KE, Buitendijk GH, Klein BE, et al. Joint Contribution of Genetic Susceptibility and Modifiable Factors to the Progression of Age-Related Macular Degeneration over 10 Years: The Three Continent AMD Consortium Report. *Ophthalmol Retina*. 2018 Jul;2(7):684–93.
- 29 Thiele S, Nadal J, Pfau M, Saßmannshausen M, von der Emde L, Fleckenstein M, et al.; Molecular Diagnostic of Age-related Macular Degeneration Study Group. Prognostic Value of Retinal Layers in Comparison with Other Risk Factors for Conversion of Intermediate Age-related Macular Degeneration. *Ophthalmol Retina*. 2020 Jan;4(1):31–40.
- 30 Chiang TT, Keenan TD, Agrón E, Liao J, Klein B, Chew EY, et al. Macular Thickness in Intermediate Age-Related Macular Degeneration Is Influenced by Disease Severity and Subretinal Drusenoid Deposit Presence. *Invest Ophthalmol Vis Sci*. 2020 Jun;61(6):59.
- 31 Waldstein SM, Vogl WD, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth U. Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography. *JAMA Ophthalmol*. 2020 Jul;138(7):740–7.
- 32 Myers CE, Klein BE, Gangnon R, Sivakumaran TA, Iyengar SK, Klein R. Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. *Ophthalmology*. 2014 Oct;121(10):1949–55.
- 33 Burlina PM, Joshi N, Pacheco KD, Freund DE, Kong J, Bressler NM. Use of Deep Learning for Detailed Severity Characterization and Estimation of 5-Year Risk Among Patients With Age-Related Macular Degeneration. *JAMA Ophthalmol*. 2018 Dec;136(12):1359–66.
- 34 Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ. The Incidence and Progression of Age-Related Macular Degeneration over 15 Years: The Blue Mountains Eye Study. *Ophthalmology*. 2015 Dec;122(12):2482–9.
- 35 Liew G, Joachim N, Mitchell P, Burlutsky G, Wang JJ. Validating the AREDS Simplified Severity Scale of Age-Related Macular Degeneration with 5- and 10-Year Incident Data in a Population-Based Sample. *Ophthalmology*. 2016 Sep;123(9):1874–8.
- 36 Abdelfattah NS, Zhang H, Boyer DS, Rosenfeld PJ, Feuer WJ, Gregori G, et al. Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye. *Invest Ophthalmol Vis Sci*. 2016 Apr;57(4):1839–46.
- 37 Alexandre de Amorim Garcia Filho C, Yehoshua Z, Gregori G, Farah ME, Feuer W, Rosenfeld PJ. Spectral-domain optical coherence tomography imaging of drusenoid pigment epithelial detachments. *Retina*. 2013 Sep;33(8):1558–66.
- 38 Seddon JM, Reynolds R, Yu Y, Rosner B. Validation of a prediction algorithm for progression to advanced macular degeneration subtypes. *JAMA Ophthalmol*. 2013 Apr;131(4):448–55.
- 39 Sitnilska V, Kersten E, Altay L, Schick T, Enders P, de Jong EK, et al. Major predictive factors for progression of early to late age-related macular degeneration. *Ophthalmologica*. 2020;243(6):444–52.
- 40 Nassisi M, Lei J, Abdelfattah NS, Karamat A, Balasubramanian S, Fan W, et al. OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study. *Ophthalmology*. 2019 Dec;126(12):1667–74.
- 41 Kim MS, Ryoo NK, Park KH. Laser and anti-vascular endothelial growth factor treatment for drusenoid pigment epithelial detachment in age-related macular degeneration. *Sci Rep*. 2020 Sep;10(1):14370.
- 42 Hsu ST, Thompson AC, Stinnett SS, Luhmann UF, Vajzovic L, Horne A, et al. Longitudinal Study of Visual Function in Dry Age-Related Macular Degeneration at 12 Months. *Ophthalmol Retina*. 2019 Aug;3(8):637–48.
- 43 Finger RP, Schmitz-Valckenberg S, Schmid M, Rubin GS, Dunbar H, Tufail A, et al.; on behalf of the MACUSTAR consortium. MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration. *Ophthalmologica*. 2019;241(2):61–72.
- 44 Terheyden JH, Holz FG, Schmitz-Valckenberg S, Lünig A, Schmid M, Rubin GS, et al.; MACUSTAR consortium. Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR. *Trials*. 2020 Jul;21(1):659.

- 45 Curcio CA, McGwin G Jr, Sadda SR, Hu Z, Clark ME, Sloan KR, et al. Functionally validated imaging endpoints in the Alabama study on early age-related macular degeneration 2 (ALSTAR2): design and methods. *BMC Ophthalmol*. 2020 May;20(1):196.
- 46 Lamin A, Dubis AM, Sivaprasad S. Changes in macular drusen parameters preceding the development of neovascular age-related macular degeneration. *Eye (Lond)*. 2019 Jun; 33(6):910–6.
- 47 Chakravarthy U, Bailey CC, Scanlon PH, McKibbin M, Khan RS, Mahmood S, et al. Progression from Early/Intermediate to Advanced Forms of Age-Related Macular Degeneration in a Large UK Cohort: Rates and Risk Factors. *Ophthalmol Retina*. 2020 Jul; 4(7):662–72.
- 48 Virgili G, Michelessi M, Parodi MB, Bacherini D, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. *Cochrane Database Syst Rev*. 2015 Oct;(10):CD006537.
- 49 Goldberg R, Gore JM, Barton B, Gurwitz J. Individual and composite study endpoints: separating the wheat from the chaff. *Am J Med*. 2014 May;127(5):379–84.
- 50 Wright C, Mazzucco AE, Becker SM, Sieving PA, Tuminia SJ. NEI-Supported Age-Related Macular Degeneration Research: Past, Present, and Future. *Transl Vis Sci Technol*. 2020 Jun;9(7):49.
- 51 Curcio CA, Zanzottera EC, Ach T, Balaratnasingam C, Freund KB. Activated Retinal Pigment Epithelium, an Optical Coherence Tomography Biomarker for Progression in Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2017;58(6):BIO211–26.
- 52 Bogunovic H, Montuoro A, Baratsits M, Karantonis MG, Waldstein SM, Schlanitz F, et al. Machine Learning of the Progression of Intermediate Age-Related Macular Degeneration Based on OCT Imaging. *Invest Ophthalmol Vis Sci*. 2017 May;58(6):BIO141–50.
- 53 Cocce KJ, Stinnett SS, Luhmann UF, Vajzovic L, Horne A, Schuman SG, et al. Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints. *Am J Ophthalmol*. 2018 May;189:127–38.
- 54 Ponderfor SG, Heinemann M, Wintergerst MW, Pfau M, Strömer AL, Holz FG, et al. Detecting vision loss in intermediate age-related macular degeneration: A comparison of visual function tests. *PLoS One*. 2020 Apr; 15(4):e0231748.
- 55 Gin TJ, Wu Z, Chew SK, Guymer RH, Luu CD. Quantitative Analysis of the Ellipsoid Zone Intensity in Phenotypic Variations of Intermediate Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2017 Apr; 58(4):2079–86.
- 56 Thiele S, Pfau M, Larsen PP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S. Multimodal Imaging Patterns for Development of Central Atrophy Secondary to Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2018 Mar;59(4):AMD1–11.
- 57 Lu L, Xu S, He F, Liu Y, Zhang Y, Wang J, et al. Assessment of Choroidal Microstructure and Subfoveal Thickness Change in Eyes With Different Stages of Age-Related Macular Degeneration. *Medicine (Baltimore)*. 2016 Mar;95(10):e2967.
- 58 Echols BS, Clark ME, Swain TA, Chen L, Kar D, Zhang Y, et al. Hyperreflective Foci and Specks Are Associated with Delayed Rod-Mediated Dark Adaptation in Nonneovascular Age-Related Macular Degeneration. *Ophthalmol Retina*. 2020 Nov;4(11):1059–68.
- 59 Ponderfor SG, Terheyden JH, Heinemann M, Wintergerst MW, Holz FG, Finger RP. Association of Vision-related Quality of Life with Visual Function in Age-Related Macular Degeneration. *Sci Rep*. 2019 Oct;9(1):15326.
- 60 Hogg RE, Silva R, Staurengi G, Murphy G, Santos AR, Rosina C, et al. Clinical characteristics of reticular pseudodrusen in the fellow eye of patients with unilateral neovascular age-related macular degeneration. *Ophthalmology*. 2014 Sep;121(9):1748–55.
- 61 Schweitzer D, Quick S, Schenke S, Klemm M, Gehlert S, Hammer M, et al. Vergleich von Parametern der zeitaufgelösten Autofluoreszenz bei Gesunden und Patienten mit früher AMD. *Ophthalmologe*. 2009 Aug; 106(8):714–22.
- 62 Lamin A, El Nokrashy A, Chandra S, Sivaprasad S. Association of Longitudinal Changes in Drusen Characteristics and Retinal Layer Volumes with Subsequent Subtype of Choroidal Neovascularisation. *Ophthalmic Res*. 2020;63(4):375–82.
- 63 Schlanitz FG, Baumann B, Kundi M, Sacu S, Baratsits M, Scheschy U, et al. Drusen volume development over time and its relevance to the course of age-related macular degeneration. *Br J Ophthalmol*. 2017 Feb;101(2):198–203.
- 64 Sleiman K, Veerappan M, Winter KP, McCall MN, Yiu G, Farsiu S, et al.; Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Optical Coherence Tomography Predictors of Risk for Progression to Non-Neovascular Atrophic Age-Related Macular Degeneration. *Ophthalmology*. 2017 Dec; 124(12):1764–77.
- 65 Schaal KB, Rosenfeld PJ, Gregori G, Yehoshua Z, Feuer WJ. Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration. *Ophthalmology*. 2016 May;123(5):1060–79.
- 66 Chauhan BC. Choosing endpoints in clinical studies and trials. *Eye (Lond)*. 2007;21 S1:S34–7.
- 67 Wu Z, Medeiros FA. Sample Size Requirements of Glaucoma Clinical Trials When Using Combined Optical Coherence Tomography and Visual Field Endpoints. *Sci Rep*. 2019 Dec;9(1):18886.
- 68 Roy NS, Wei Y, Kuklinski E, Asbell PA. The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research. *Invest Ophthalmol Vis Sci*. 2017 May; 58(6):BIO1–19.
- 69 Villani E, Bonsignore F, Cantalamessa E, Serafino M, Nucci P. Imaging Biomarkers for Dry Eye Disease. *Eye Contact Lens*. 2020 Mar; 46 Suppl 2:S141–5.
- 70 Schneider LS, Goldberg TE. Composite cognitive and functional measures for early stage Alzheimer's disease trials. *Alzheimers Dement (Amst)*. 2020 May;12(1):e12017.
- 71 Schuster Bruce C, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. *PLoS Med*. 2019 Sep; 16(9):e1002873.